시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
유전성 혈관부종 치료제 시장 규모, 점유율, 성장 분석 : 치료법별, 투여 경로별, 유통 채널별, 최종 용도별, 지역별 - 산업 예측(2025-2032년)
Hereditary Angioedema Treatment Market Size, Share, Growth Analysis, By Treatment, By Route of Administration, By Distribution Channel, By End Use, By Region - Industry Forecast 2025-2032
상품코드 : 1630607
리서치사 : SkyQuest
발행일 : 2025년 01월
페이지 정보 : 영문 157 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,890,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 9,230,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,570,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 유전성 혈관부종 치료제 시장 규모는 2023년에 27억 달러로 평가되며, 2024년 27억 7,000만 달러에서 2032년에는 33억 7,000만 달러로 성장할 전망이며, 예측 기간(2025-2032년)의 CAGR은 2.5%입니다.

헬스케어 분야 시장 확대는 희귀질환, 특히 유전성 혈관부종(HAE)에 대한 치료의 필요성을 인식하게된 것이 큰 원동력이 되고 있습니다. 이 질환은 약 50,000명 중 1명이 앓고 있으며, 전 세계 유병률은 150,000명 중 1명입니다. 신체 여러 부위의 갑작스러운 부종을 특징으로 하는 혈관부종 발작의 발생률이 증가함에 따라 미국 유전성 혈관부종 협회(US Hereditary Angioedema Association)와 같은 단체가 최신 치료 옵션과 환자 지원을 옹호하는 등 환자 인식 제고에 힘쓰고 있습니다. 최근 조사에 따르면 의료진들은 유전성 혈관부종 관리의 진전을 보고하고 있으며, 새로운 치료법이 환자의 치료 결과와 만족도를 향상시키고 있다고 보고하고 있습니다. 인도에는 약 30,000-50,000명의 유전성 혈관부종 환자가 있으며, 주로 피부과 전문의, 소화기내과 전문의, 임상 알레르기 전문의가 이 질환을 치료하고 있는 것으로 추정됩니다.

목차

서론

조사 방법

개요

시장 역학과 전망

주요 시장 인사이트

유전성 혈관부종 치료제 시장 규모 : 치료별

유전성 혈관부종 치료제 시장 규모 : 투여 경로별

유전성 혈관부종 치료제 시장 규모 : 유통 채널별

유전성 혈관부종 치료제 시장 규모 : 최종 용도별

유전성 혈관부종 치료제 시장 규모

경쟁 정보

주요 기업 개요

결론과 권장사항

KSA
영문 목차

영문목차

Global Hereditary Angioedema Treatment Market size was valued at USD 2.7 billion in 2023 and is poised to grow from USD 2.77 billion in 2024 to USD 3.37 billion by 2032, growing at a CAGR of 2.5% during the forecast period (2025-2032).

Market expansion in the healthcare sector is significantly driven by the growing recognition of the need for treatments for rare disorders, notably hereditary angioedema (HAE). This condition affects approximately 1 in 50,000 individuals, with a global prevalence of 1 in 150,000. The increasing incidence of angioedema attacks, characterized by sudden swelling in various body regions, is leading to heightened awareness efforts by organizations like the US Hereditary Angioedema Association, which advocates for modern treatment options and support for patients. Recent surveys show that healthcare professionals have reported advancements in HAE management, with improved patient outcomes and satisfaction due to novel therapies. In India, an estimated 30,000-50,000 individuals suffer from HAE, predominantly treated by dermatologists, gastroenterologists, and clinical allergists.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hereditary Angioedema Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hereditary Angioedema Treatment Market Segmental Analysis

Global Hereditary Angioedema Treatment Market is segmented by Treatment, Route of Administration, Distribution Channel, End Use and region. Based on Treatment, the market is segmented into C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor and Others. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Others. Based on End Use, the market is segmented into Prophylaxis and On-demand. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hereditary Angioedema Treatment Market

The global hereditary angioedema treatment market is significantly driven by a heightened focus on advanced therapeutics aimed at managing these disorders. Researchers and manufacturers worldwide are diligently working to develop and enhance therapies for hereditary angioedema, as evidenced by numerous new medication applications for C1-esterase inhibitors, Bradykinin B2 receptor antagonists, and Kallikrein inhibitors targeting Types I, II, and III HAE. This surge in sophisticated treatment options, coupled with rising awareness and the increasing prevalence of rare diseases, has accelerated market growth. Recent approvals of innovative medications and a promising pipeline for future drug developments further bolster this expansion, alongside the growing impact of severe edema episodes linked to elevated estrogen levels and ACE inhibitor usage.

Restraints in the Global Hereditary Angioedema Treatment Market

The growth of the global hereditary angioedema treatment market is significantly hindered by the frequent misdiagnosis of the condition, often mistaken for common allergies, appendicitis, and irritable bowel syndrome. This misidentification stems from a widespread lack of awareness regarding hereditary angioedema (HAE), resulting in inadequate treatment for those affected. Consequently, many individuals suffering from HAE receive incorrect diagnoses, frequently being categorized under gastrointestinal disorders or non-allergic angioedema, thereby delaying appropriate care. This prevalent issue not only disrupts the treatment process for patients but also stifles advancements and expansion within the hereditary angioedema treatment market as a whole.

Market Trends of the Global Hereditary Angioedema Treatment Market

The Global Hereditary Angioedema (HAE) Treatment market is witnessing significant growth driven by increased awareness of rare conditions and the emergence of innovative therapies. Key catalysts include the introduction of novel therapeutics and pipeline medications, exemplified by recent products like Takhzyro (lanadelumab), which addresses prophylactic HAE treatment. A notable trend is the shift towards oral delivery methods, enhancing patient convenience and minimizing adverse effects compared to traditional treatments. As pharmaceutical companies explore the rare disease sector, the influx of new entrants with promising products suggests a competitive landscape poised for expansion. This dynamic environment is expected to further accelerate market growth and improve treatment accessibility for HAE patients globally.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Hereditary Angioedema Treatment Market Size by Treatment & CAGR (2025-2032)

Global Hereditary Angioedema Treatment Market Size by Route of Administration & CAGR (2025-2032)

Global Hereditary Angioedema Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Global Hereditary Angioedema Treatment Market Size by End Use & CAGR (2025-2032)

Global Hereditary Angioedema Treatment Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기